Gerald A. Brunk
CIK: 0001380226
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)2 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
ENGN
enGene Therapeutics Inc.
Director
Discretionary Trading P&L
Holdings
About BRUNK GERALD A
BRUNK GERALD A (SEC CIK 0001380226) files insider reports with the SEC as Director of enGene Therapeutics Inc. (ENGN).
Signal8 holds 2 ownership filings by BRUNK GERALD A, all Form 4s, filed between Jun 16, 2025 and Jun 17, 2026. Those filings report 2 transactions, from Jun 16, 2025 to Jun 16, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on BRUNK GERALD A's filings is in SAINT-LAURENT.
Recent filings by BRUNK GERALD A
Other insiders filing for enGene Therapeutics Inc. (ENGN)
- Grossman William, Interim Chief Medical Officer
- Chinoporos Constantine, Interim Chief Business Officer
- Richton Kathleen P., SVP, Finance and Treasurer
- Astley-Sparke Philip, Director
- Glickman Richard M, Director
- HASTINGS PAUL J, Director